Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + carboplatin + nab-paclitaxel or paclitaxel
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This chemoimmunotherapy combination regimen is used as a standard-of-care control in clinical trials for squamous non-small cell lung cancer (NSCLC). It consists of the anti-PD-1 monoclonal antibody pembrolizumab, the platinum-based alkylating agent carboplatin, and a taxane chemotherapy agent, which can be either nab-paclitaxel or paclitaxel at the investigator's discretion. Pembrolizumab functions by blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby enhancing T-cell mediated anti-tumor immune responses. Carboplatin induces DNA cross-linking to inhibit replication, while the taxane component (paclitaxel or nab-paclitaxel) stabilizes microtubules to prevent cell division. This specific combination is being utilized by ImmunityBio, Inc. as the reference treatment in the QUILT-2.023 Phase 3 study.
- Other names
- Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice)
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pembrolizumab + carboplatin + nab-paclitaxel or paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + carboplatin + nab-paclitaxel or paclitaxel.